Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study

Journal of the American Academy of Dermatology

Volumn 58, Issue 3, 2008, Pages 421-429

  Brauchli, Yolanda B ^a   Jick, Susan S ^b   Curtin, François ^c   Meier, Christoph R ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c MERCK SERONO S A   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; BIGUANIDE DERIVATIVE; CALCIPOTRIOL; COAL TAR; DITHRANOL; ETRETIN; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TAZAROTENE; TROGLITAZONE;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DRUG EXPOSURE; FEMALE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSORIASIS; RISK; STATISTICAL ANALYSIS; UNITED KINGDOM;

ADMINISTRATION, ORAL; ADULT; AGED; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PRESCRIPTIONS, DRUG; PSORIASIS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 39149102510     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.11.023     Document Type: Article

References (38)

1. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 3 (2004) 121-128
2. Raychaudhuri S.P., and Farber E.M. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 15 (2001) 16-17
3. Gelfand J.M., Weinstein R., Porter S.B., Neimann A.L., Berlin J.A., and Margolis D.J. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 141 (2005) 1537-1541
4. Gudjonsson J.E., Johnston A., Sigmundsdottir H., and Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 135 (2004) 1-8
5. Pershadsingh H.A., Sproul J.A., Benjamin E., Finnegan J., and Amin N.M. Treatment of psoriasis with troglitazone therapy. Arch Dermatol 134 (1998) 1304-1305
6. Ellis C.N., Varani J., Fisher G.J., Zeigler M.E., Pershadsingh H.A., Benson S.C., et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol 136 (2000) 609-616
7. Yang X.Y., Wang L.H., Chen T., Hodge D.R., Resau J.H., DaSilva L., et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists: PPARgamma co-association with transcription factor NFAT. J Biol Chem 275 (2000) 4541-4544
8. Krueger J.G. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46 (2002) 1-23
9. Clark R.B., Bishop-Bailey D., Estrada-Hernandez T., Hla T., Puddington L., and Padula S.J. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 164 (2000) 1364-1371
10. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7 (2001) 48-52
11. Bongartz T., Coras B., Vogt T., Scholmerich J., and Muller-Ladner U. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford) 44 (2005) 126-129
12. Robertshaw H., and Friedmann P.S. Pioglitazone: a promising therapy for psoriasis. Br J Dermatol 152 (2005) 189-191
13. Pershadsingh H.A., Benson S.C., and Ellis C.N. Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient. Skinmed 4 (2005) 386-390
14. Shafiq N., Malhotra S., Pandhi P., Gupta M., Kumar B., and Sandhu K. Pilot trial: pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol 44 (2005) 328-333
15. Ellis C.N., Barker J.N., Haig A.E., Parker C.A., Daly S., and Jayawardene D.A. Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone. Am J Clin Dermatol 8 (2007) 93-102
16. Varani J., Bhagavathula N., Ellis C.N., and Pershadsingh H.A. Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease. Expert Opin Investig Drugs 15 (2006) 1453-1468
17. Koca R., Altinyazar H.C., Yenidunya S., and Tekin N.S. Psoriasiform drug eruption associated with metformin hydrochloride: a case report. Dermatol Online J 9 (2003) 11
18. Goh C.L. Psoriasiform drug eruption due to glibenclamide. Australas J Dermatol 28 (1987) 30-32
19. Babad F. Psoriasis and phenformin hydrochloride: a report on 2 cases. J Med Soc N J 71 (1974) 412
20. Garcia Rodriguez L.A., and Perez Gutthann S. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 45 (1998) 419-425
21. Jick H. A database worth saving. Lancet 350 (1997) 1045-1046
22. Lawson D.H., Sherman V., and Hollowell J. The general practice research database. QJM 91 (1998) 445-452
23. Walley T., and Mantgani A. The UK general practice research database. Lancet 350 (1997) 1097-1099
24. Jick H., Jick S.S., and Derby L.E. Validation of information recorded on general practitioner based computerized data resource in the United Kingdom. BMJ 302 (1991) 766-768
25. Jick S.S., Kaye J.A., Vasilakis-Scaramozza C., Garcia Rodriguez L.A., Ruigomez A., Meier C.R., et al. Validity of the general practice research database. Pharmacotherapy 23 (2003) 686-689
26. Jick H., Terris B.Z., Derby L.E., and Jick S.S. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1 (1992) 347-349
27. Gelfand J.M., Berlin J., Van Voorhees A., and Margolis D.J. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 139 (2003) 1425-1429
28. Neimann A.L., Shin D.B., Wang X., Margolis D.J., Troxel A.B., and Gelfand J.M. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55 (2006) 829-835
29. Gelfand J.M., Neimann A.L., Shin D.B., Wang X., Margolis D.J., and Troxel A.B. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006) 1735-1741
30. Gelfand J.M., Shin D.B., Neimann A.L., Wang X., Margolis D.J., and Troxel A.B. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 126 (2006) 2194-2201
31. Gelfand J.M., Wang X., Qing L., Neimann A.L., Weinstein R., and Margolis D.J. Epidemiology and treatment patterns of psoriasis in the general practice research database (GPRD). Pharmacoepidemiol Drug Saf 14 Suppl (2005) S23
32. Ruderman N., and Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 3 (2004) 340-351
33. Stocker D.J., Taylor A.J., Langley R.W., Jezior M.R., and Vigersky R.A. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 153 (2007) 445.e1-6
34. Henseler T., and Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 32 (1995) 982-986
35. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica 172 (1986) 298-304
36. Pearce D.J., Morrison A.E., Higgins K.B., Crane M.M., Balkrishnan R., Fleischer Jr. A.B., et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatol Treat 16 (2005) 319-323
37. Sommer D.M., Jenisch S., Suchan M., Christophers E., and Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298 (2006) 321-328
38. Shapiro J., Cohen A.D., David M., Hodak E., Chodik G., Viner A., et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 56 (2007) 629-634